ALKS completes Vivitrex Phase III enrollment

Alkermes (ALKS) completed enrollment of about 600 alcohol-dependent patients in a Phase III trial of its Vivitrex injectable extended-release naltrexone. Patients in the double-blind, placebo-controll...